C4 Therapeutics (CCCC) Cash from Investing Activities Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 26.37% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -89.24% |
| 10 | C4 Therapeutics | 499.92 Mn | 246.25 Mn | - | -138.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -138.06% |
| Mar 31, 2026 | -44.54% |
| Dec 31, 2025 | -690.59% |
| Sep 30, 2025 | 2,422.22% |
| Jun 30, 2025 | 432.49% |
| Mar 31, 2025 | 154.55% |
| Dec 31, 2024 | -57.21% |
| Sep 30, 2024 | -99.72% |
| Jun 30, 2024 | -177.28% |
| Mar 31, 2024 | -199.75% |
| Dec 31, 2023 | 244.09% |
| Sep 30, 2023 | 189.87% |
| Jun 30, 2023 | -54.41% |
| Mar 31, 2023 | 1,436.94% |
| Dec 31, 2022 | 115.63% |
| Sep 30, 2022 | 119.79% |
| Jun 30, 2022 | 2.45% |
| Mar 31, 2022 | 93.51% |
| Dec 31, 2021 | -9.68% |
| Sep 30, 2021 | -211.34% |